Keytruda (pembrolizumab) targets PD-1, a receptor on immune cells that acts as a brake, and blocking this brake enhances anti-tumor immunity.

“the target of Kuda just for those who are trying to keep up with the jargon as they do their their Google searching on any of these topics the target of katuda um is P capital P capital D hyen one that's a surface receptor on certain immune cells um particularly on these cd8 positive T lymphocytes that can kill tumors directly but there are other immune cells that um Express pd1 and so and that's a break on those immune cells so the antibodies that block that break are the so-called pd1 antibodies”